Health & Environmental Research Online (HERO)


Print Feedback Export to File
6986581 
Journal Article 
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and >= 50 years old adults 
Jo, Ana; Villanueva, N; Lakio, S; Morton, DAV; Ralph, AP; Lambert, P; Pillet, S; Couillard, J; Trepanier, S; Poulin, JF; Yassine-Diab, B; Guy, B; Ward, BJ; Landry, N 
2019 
1 
PLoS ONE
EISSN: 1932-6203 
14 
6 
English 
31166987 
WOS:000470087800011 
New influenza vaccines eliciting more effective protection are needed, particularly for the elderly who paid a large and disproportional toll of hospitalization and dead during seasonal influenza epidemics. Low (≤15 μg/strain) doses of a new plant-derived virus-like-particle (VLP) vaccine candidate have been shown to induce humoral and cellular responses against both homologous and heterologous strains in healthy adults 18-64 years of age. The two clinical trials reported here addressed the safety and immunogenicity of higher doses (≥15 μg/strain) of quadrivalent VLP candidate vaccine on 18-49 years old and ≥50 years old subjects. We also investigated the impact of alum on the immunogenicity induced by lower doses of the vaccine candidate.